Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)-Reference-Cited by-同舟云学术

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

Published:2019-07-12 Issue:1 Volume:19 Page:
ISSN:1471-2261
Container-title:BMC Cardiovascular Disorders
language:en
Short-container-title:BMC Cardiovasc Disord

Author:

De Caterina Raffaele, ,Kelly Peter,Monteiro Pedro,Deharo Jean Claude,de Asmundis Carlo,López-de-Sá Esteban,Weiss Thomas W.,Waltenberger Johannes,Steffel Jan,de Groot Joris R.,Levy Pierre,Bakhai Ameet,Zierhut Wolfgang,Laeis Petra,Kerschnitzki Michael,Reimitz Paul-Egbert,Kirchhof Paulus^ORCID

Funder

This study was funded by Daiichi Sankyo Europe GmbH, Munich, Germany

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12872-019-1144-x.pdf

Reference28 articles.

1. Sankaranarayanan R, Kirkwood G, Visweswariah R, Fox DJ. How does chronic atrial fibrillation influence mortality in the modern treatment era? Curr Cardiol Rev. 2015;11(3):190–8.

2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

3. Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost. 2014;111(5):933–42.